Cyrano Therapeutics and Resyca Announce Exclusive License Agreement for Soft Mist Nasal Spray Technology for the Treatment of Chemosensory Dysfunction
DELRAY BEACH, Fla and ENSCHEDE, Netherlands, March 18, 2025 /PRNewswire/ — Cyrano Therapeutics, a clinical-stage regenerative medicine company pioneering the development of treatments for smell loss, and Resyca, a leading innovator in soft mist inhaler and soft nasal spray technologies, today announced they have entered into an exclusive licensing agreement for Resyca’s proprietary soft mist nasal spray technology for the treatment of chemosensory disorders, including post-viral smell loss (hyposmia).
This agreement marks a major milestone in advancing an innovative treatment to address this critical unmet medical need. Cyrano Therapeutics’ lead therapy, CYR-064, has progressed its Phase 2 FLAVOR clinical study utilizing Resyca’s soft mist nasal spray technology, with top-line data expected in the second half of 2025…..